11/05/2026
Haematology News Update for 11 May 2026
Haematology is quietly becoming one of the clearest examples of where modern medicine is headed: earlier immunotherapy, less chemotherapy, more molecular selection, and much more expensive standards of care.
This week’s updates make that hard to ignore.
In multiple myeloma, the direction is obvious. Teclistamab + daratumumab moves bispecific therapy earlier into relapsed disease, while D-VRd pushes frontline treatment in transplant-ineligible patients further towards quadruplet intensity. The science is exciting. But the real-world question is whether health systems can keep up. Every “new standard” sounds impressive until you ask who can access it, who can monitor the toxicities, and who will still be left on older regimens because funding says no.
In CLL, acalabrutinib + venetoclax as a first-line, all-oral, fixed-duration option feels like the kind of progress doctors and patients actually want. Less chemotherapy, no endless treatment if it can be avoided, and a regimen that fits real life better. But again, the debate is no longer just about efficacy. It is about affordability, sequencing, and what happens when several “better” options all arrive at once.
In AML, ziftomenib adds another targeted option for NPM1-mutated relapsed/refractory disease. That is welcome progress. But it also highlights a deeper issue: targeted therapy only helps if your system can actually deliver fast, reliable molecular diagnosis.
The benign haematology updates matter too, especially in aplastic anaemia and paediatric VTE. Not every important advance is a new drug. Sometimes real progress is clearer guidance, less variation in care, and more confidence about when to escalate treatment.
And in transplant/cellular therapy, it is probably time to stop talking about CAR-T as if it sits outside mainstream haematology planning. It does not. Updated EBMT recommendations make that increasingly clear. Cellular therapy is now part of the core decision-making pathway, not a side conversation.
My take: the science is moving fast, but the bigger challenge now is whether practice, funding, and infrastructure can move with it. In haematology, the widening gap between what is possible and what is deliverable may become the most important story of all.
